Pareteum Is Booming
Pareteum is booming, yet shareholders have to exert a little more patience as the share count is ten-folding in the space of a couple of years. The acquisition of Artilium […]
Pareteum is booming, yet shareholders have to exert a little more patience as the share count is ten-folding in the space of a couple of years. The acquisition of Artilium […]
China has a reputation for being a currency manipulator, having mercantilist trade practices, glaring disrespect for IP and depending on exports for growth. While these things were all true in […]
Given the opportunities for profits for entrenched players in the US healthcare system, we expected a SaaS player with incredible datasets to be one of these. Despite continuously increasing these […]
For now, it has paid off buying the dips induced by increasing trade tensions. But as the economic damage of every new round of escalation increases, one can’t count on […]
The company has made a successful shift towards header-bidding, where it has acquired and developed a couple of advantages. While revenues are still hampered by the elimination of the buy-side […]
The company managed to squeeze its first (non-GAAP) profitability in quite a while and things look set to improve from here. As a white label solution, it has an interesting […]
Their continuous glucose monitoring sensor Eversense is set to take the considerable market share and even broaden it as it has important advantages. So expect some explosive revenue growth in […]
One of the most epic stock rallies we’ve ever seen, Tandem Diabetes Care looked down and out late last year, but its fortunes have revived in the most dramatic fashion […]
Assuming rational actors, a further escalation in the US trade war with China doesn’t make sense, as the upside is limited and the potential downside rather large. It is rational […]
The best investments, the ones that build fortunes, are the home runs of companies beaten down. It is of course very difficult to spot these opportunities and you’ll have to […]